Our next Company Snapshot for next week’s BIO Investor Forum is Chimerix. They will be presenting on Tuesday, at 1:30pm, and will also be participating in a panel at the event, Choose Your Own Adventure — Late Stage Private Company Decisions on Wednesday. To learn more about the company before you get onsite, continue reading!
What is your company’s lead product or technology?
Chimerix’s lead product is CMX001, a novel, broad-spectrum, oral antiviral that inhibits double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV) and BK virus (BKV). CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV in hematopoietic stem cell transplant (HSCT) recipients and is in Phase 2 development for the preemption and treatment of AdV infection. To date, more than 800 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment protocols. Chimerix is planning to initiate Phase 3 clinical development of CMX001 for the prophylaxis of CMV in HSCT recipients in early 2013.
How does your company go about differentiating itself from the competition?
CMX001 is a broad spectrum antiviral that inhibits multiple viruses, such as CMV, AdV, and BKV. Currently available therapies are narrow spectrum and inhibit only a single virus, mainly CMV. There are no specific approved therapies to treat AdV and BKV populations. Furthermore, there is no approved therapy for prophylaxis of CMV in HSCT recipients. Available therapies are approved for solid organ transplant recipients and are associated with serious side effects that limit their use. In dosing over 800 subjects, CMX001 has not been shown to be associated with the toxicities of current therapies.
What are the short-term and long-term priorities for your company?
Chimerix’s top priority is initiating our Phase 3 CMV study evaluating CMX001 in HSCT recipients and, thereafter, applying for FDA approval so we can launch the drug.
Tell us something about your company that investors might not know.
In addition to our commercial program, Chimerix is also developing CMX001 as a medical countermeasure to protect against a bioterror threat in the event of a smallpox release. This work is being funded under a contract from the Biomedical Advanced Research and Development Authority (BARDA).
We thank Chimerix for their time and participation at next week’s event, and safe travels to all the attendees!